Hemolytic disease of fetus and newborn course, management and outcomes - an analysis based on the Israeli Maccabi database-Reference-Cited by-同舟云学术

Hemolytic disease of fetus and newborn course, management and outcomes - an analysis based on the Israeli Maccabi database

Published:2024-07-19 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Fallach Noga¹,Hoshen Moshe¹,Gazit Sivan¹,Segal Yaakov¹,Fitzgibbon Marie²,Karmous Wisam²,Barthelmes Norma²,Iqbal Sofia²,Borsi Andras²,Noel Wim²,Mandel Dror³,Yinon Yoav⁴

Affiliation:

1. Kahn-Sagol-Maccabi Research and Innovation Institute

2. Janssen Pharmaceuticals NV

3. Dana Dwek Children's Hospital, Neonatal Intensive Care Unit, Neonatalogy, Tel Aviv University

4. Sheba Medical Center

Abstract

Objective: Hemolytic disease of the fetus and newborn (HDFN) can cause severe prenatal and postnatal outcomes. The main objective of this study is to understand the clinical impact of HDFN on pregnant women and newborns. Study Design: A retrospective cohort study was performed on de-identified data extracted from a large nationwide health organization. The cohort included women and newborns diagnosed with HDFN between 1998-2021. Cohort characteristics and outcomes are described. Result: Over the 24-year study period, incidence rate of HDFN among pregnant women was stable while incidence rate among newborns declined. Severe HDFN was diagnosed in 28.8% of 73 HDFN affected pregnancies. One third of 450 HDFN newborns were diagnosed with anemia or jaundice; 5 cases of kernicterus were observed. Conclusion: Severe prenatal and postnatal outcomes following HDFN were observed. Further studies are needed to evaluate treatment regimens and assess the association between treatment management and short- and long-term outcomes.

Publisher

Springer Science and Business Media LLC

Reference21 articles.

1. Haemolytic disease of the fetus and newborn;Haas M;Vox sanguinis,2015

2. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn;Bennardello F;Blood Transfusion,2015

3. Costumbrado J, Mansour T, Ghassemzadeh S. Rh incompatibility. StatPearls [Internet]. StatPearls Publishing; 2022.

4. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology 2014, the American Society of Hematology Education Program Book. 2015;2015(1):146–151.

5. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn–review on current management and outcome;Zwiers C;Expert review of hematology,2017